Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

被引：0
作者：
Seung Hyun Kang
Chang-Han Lee
机构：
[1] Seoul National University College of Medicine,Department of Pharmacology
[2] Seoul National University College of Medicine,Department of Biomedical Sciences
[3] Seoul National University College of Medicine,SNU Dementia Research Center
来源：
Biotechnology and Bioprocess Engineering | 2021年 / 26卷
关键词：
therapeutic antibody; antibody engineering; Fc engineering; bispecific antibody;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Monoclonal antibodies (mAb) have been used as therapeutic agents for various diseases, and immunoglobulin G (IgG) is mainly used among antibody isotypes due to its structural and functional properties. So far, regardless of the purpose of the therapeutic antibody, wildtype IgG has been mainly used, but recently, the engineered antibodies with various strategies according to the role of the therapeutic antibody have been used to maximize the therapeutic efficacy. In this review paper, first, the overall structural features and functional characteristics of antibody IgG, second, the old and new techniques for antibody discovery, and finally, several antibody engineering strategies for maximizing therapeutic efficacy according to the role of a therapeutic antibody will be introduced.
引用
收藏
页码：295 / 311
页数：16
相关论文
共 1056 条
[1]  
Scott A M(2012)Antibody therapy of cancer Nat. Rev. Cancer. 12 278-287
[2]  
Wolchok J D(2010)Monoclonal antibodies: Versatile platforms for cancer Immunotherapy Nat. Rev. Immunol. 10 317-327
[3]  
Old L J(2014)How immunoglobulin G antibodies kill target cells: Revisiting an old paradigm Adv. Immunol. 124 67-94
[4]  
Weiner L M(2019)Selecting and engineering monoclonal antibodies with drug-like specificity Curr. Opin. Biotechnol. 60 119-127
[5]  
Surana R(2018)Current progress in innovative engineered antibodies Protein Cell. 9 86-120
[6]  
Wang S(2017)Antibody isotypes for tumor immunotherapy Transfus Med. Hemother. 44 320-326
[7]  
Biburger M(2015)Cancer immunotherapy: Harnessing the immune system to battle cancer J. Clin. Invest. 125 3335-3337
[8]  
Lux A(2015)Differential Fc-receptor engagement drives an anti-tumor vaccinal effect Cell. 161 1035-1045
[9]  
Nimmerjahn F(2015)Building better monoclonal antibody-based therapeutics Nat. Rev. Cancer. 15 361-370
[10]  
Starr C G(2014)Antibody Fc: Linking adaptive and innate immunity MAbs. 6 619-621
12345678910